Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
RXII's Cash to Debt is ranked higher than
74% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. RXII: No Debt )
Ranked among companies with meaningful Cash to Debt only.
RXII' s 10-Year Cash to Debt Range
Min: 0.35  Med: 9999.00 Max: No Debt
Current: No Debt
Equity to Asset 0.35
RXII's Equity to Asset is ranked lower than
81% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. RXII: 0.35 )
Ranked among companies with meaningful Equity to Asset only.
RXII' s 10-Year Equity to Asset Range
Min: -1.04  Med: 0.37 Max: 0.52
Current: 0.35
-1.04
0.52
Interest Coverage No Debt
RXII's Interest Coverage is ranked lower than
57% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. RXII: No Debt )
Ranked among companies with meaningful Interest Coverage only.
RXII' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 2
Z-Score: -10.97
M-Score: -5.11
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -12476.32
RXII's Operating margin (%) is ranked lower than
94% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. RXII: -12476.32 )
Ranked among companies with meaningful Operating margin (%) only.
RXII' s 10-Year Operating margin (%) Range
Min: -13376.29  Med: -12430.99 Max: -5250.38
Current: -12476.32
-13376.29
-5250.38
Net-margin (%) -12448.68
RXII's Net-margin (%) is ranked lower than
94% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. RXII: -12448.68 )
Ranked among companies with meaningful Net-margin (%) only.
RXII' s 10-Year Net-margin (%) Range
Min: -13278.35  Med: -12394.37 Max: -5244.36
Current: -12448.68
-13278.35
-5244.36
ROE (%) -263.88
RXII's ROE (%) is ranked lower than
93% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. RXII: -263.88 )
Ranked among companies with meaningful ROE (%) only.
RXII' s 10-Year ROE (%) Range
Min: -336.41  Med: -336.41 Max: -336.41
Current: -263.88
ROA (%) -90.50
RXII's ROA (%) is ranked lower than
84% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. RXII: -90.50 )
Ranked among companies with meaningful ROA (%) only.
RXII' s 10-Year ROA (%) Range
Min: -353.55  Med: -203.85 Max: -72.95
Current: -90.5
-353.55
-72.95
ROC (Joel Greenblatt) (%) -5238.67
RXII's ROC (Joel Greenblatt) (%) is ranked lower than
80% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. RXII: -5238.67 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RXII' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -13106.06  Med: -11172.80 Max: -4903.33
Current: -5238.67
-13106.06
-4903.33
» RXII's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

RXII Guru Trades in

RXII Guru Trades in

RXII Guru Trades in

Q1 2015

RXII Guru Trades in Q1 2015

Jim Simons 21,200 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with RXII

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.88
RXII's P/B is ranked lower than
59% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. RXII: 5.88 )
Ranked among companies with meaningful P/B only.
RXII' s 10-Year P/B Range
Min: 2.43  Med: 11.67 Max: 50
Current: 5.88
2.43
50
Current Ratio 4.49
RXII's Current Ratio is ranked higher than
51% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. RXII: 4.49 )
Ranked among companies with meaningful Current Ratio only.
RXII' s 10-Year Current Ratio Range
Min: 0.48  Med: 6.92 Max: 11.98
Current: 4.49
0.48
11.98
Quick Ratio 4.49
RXII's Quick Ratio is ranked higher than
53% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. RXII: 4.49 )
Ranked among companies with meaningful Quick Ratio only.
RXII' s 10-Year Quick Ratio Range
Min: 0.48  Med: 6.92 Max: 11.98
Current: 4.49
0.48
11.98

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.83
RXII's Price/Net Cash is ranked higher than
53% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 8.40 vs. RXII: 7.83 )
Ranked among companies with meaningful Price/Net Cash only.
RXII' s 10-Year Price/Net Cash Range
Min: 6.14  Med: 10.53 Max: 17.78
Current: 7.83
6.14
17.78
Price/Net Current Asset Value 6.71
RXII's Price/Net Current Asset Value is ranked higher than
56% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. RXII: 6.71 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
RXII' s 10-Year Price/Net Current Asset Value Range
Min: 8.33  Med: 14.00 Max: 40
Current: 6.71
8.33
40
Price/Tangible Book 5.88
RXII's Price/Tangible Book is ranked higher than
50% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. RXII: 5.88 )
Ranked among companies with meaningful Price/Tangible Book only.
RXII' s 10-Year Price/Tangible Book Range
Min: 8.14  Med: 13.19 Max: 35.58
Current: 5.88
8.14
35.58
Earnings Yield (Greenblatt) (%) -90.89
RXII's Earnings Yield (Greenblatt) (%) is ranked lower than
96% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. RXII: -90.89 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RXII' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -90.89  Med: 1599.30 Max: 6541.7
Current: -90.89
-90.89
6541.7

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:44R.Germany,
RXi Pharmaceuticals Corp was incorporated in Delaware on September 8, 2011. It is a biotechnology company focused on discovering and developing therapies addressing high unmet medical needs, in the areas of dermatology and ophthalmology. Its development programs are based on siRNA technology and immunotherapy agents. The clinical development programs include, but are not limited to, its proprietary, self-delivering RNAi (sd-rxRNA) compounds for the treatment of dermal and retinal scarring and an immunodulating agent, Samcyprone, for the treatment of such disorders as alopecia areata, warts and cutaneous metastases of melanoma. In addition to these clinical programs, the Company has a pipeline of discovery and preclinical product candidates in its core therapeutic areas, as well as in other areas of interest. The Company's pipeline, coupled with its extensive patent portfolio, provides for the advancement to further discover and develops therapies either on its own or in collaboration with strategic partners. The Company's first clinical product candidate is RXI-109, a self-delivering RNAi compound being developed for the reduction of dermal scar formation. RXI-109 is designed to reduce the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin. RXI-109 is being developed to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids. The Company competes with Alnylam Pharmaceuticals, Inc., Benitec Limited, Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Dicerna Pharmaceuticals, Inc., Sylentis, S.A. and Roche Innovation Center Copenhagen A/S. The Company is subject to federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials.
» More Articles for RXII

Headlines

Articles On GuruFocus.com
Looking Ahead of Wall Street: RXI Pharmaceuticals, Titan Pharmaceuticals, Micron Technologies Mar 30 2015 
comment on RXII Mar 09 2013 
RXi Pharmaceuticals Corp. (RXII) CEO Noah D Beerman buys 10,000 Shares Jul 12 2010 
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2009 Aug 14 2009 
CytRx Reports 2009 Second Quarter Financial Results Aug 10 2009 

More From Other Websites
Summers Small Cap Stock Portfolio Jun 26 2015
RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Novel RNAi Platform Jun 09 2015
The Rising Tide in Larger Markets Spurs New Interest In Small-Cap Stocks Jun 08 2015
RXI PHARMACEUTICALS CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 04 2015
3 Stocks Under $10 to Trade for Breakouts Jun 04 2015
RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use... Jun 03 2015
RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology Jun 02 2015
RXi Pharmaceuticals' CEO Dr. Geert Cauwenbergh Interviewed by The Life Sciences Report Jun 01 2015
RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants May 28 2015
RXI PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... May 28 2015
RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants May 27 2015
RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock May 27 2015
RXi Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference May 26 2015
RXI PHARMACEUTICALS CORP Financials May 22 2015
RXi (RXII) Q1 Loss Wider-Than-Expected, Pipeline in Focus - Analyst Blog May 14 2015
RXI PHARMACEUTICALS CORP Files SEC form 8-K, Results of Operations and Financial Condition,... May 13 2015
Q1 2015 Rxi Pharmaceuticals Corp Earnings Release - After Market Close May 13 2015
RXI PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report May 13 2015
RXi Pharmaceuticals Reports First Quarter 2015 Financial Results and Business Highlights May 13 2015
RXi Pharmaceuticals Presented Promising New Data with Self-delivering RNAi Compounds Targeting... May 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK